Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07636148

Registry of Minimally Invasive Cancer Treatment Using Spectral Angio-CT Image Guidance

This study collects data from patients undergoing minimally invasive, image-guided cancer treatments at participating hospitals in the Netherlands and France. All treatments are performed as standard clinical care and include procedures such as tumor ablation and catheter-based treatments of cancer in the liver, kidney, lung, and bone.

During these procedures, a spectral angio-CT system is used for image guidance. This advanced CT scanner automatically captures additional imaging information beyond what is used in routine clinical decision-making. The goal of this study is to investigate how this additional imaging information is associated with treatment outcomes, and how it can be used in the future to improve treatment planning, procedural guidance, and prediction of treatment results.

No experimental interventions are performed. Participation does not alter the treatment or follow-up patients receive. Data are collected from medical records and imaging systems and stored securely for analysis.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Liver Cancer (Primary and Metastatic) Adenocarcinoma Bone Cancer Metastatic Bone Cancer Tumor Bone Diseases Bone Neoplasms Bone Tumors Carcinoma Carcinoma, Hepatocellular Carcinoma, Renal Cell Digestive System Diseases Digestive System Neoplasms Disease Disease Attributes Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Hepatocellular Carcinoma (HCC) Kidney Diseases Kidney Neoplasms Kidney Tumors Liver Diseases Liver Neoplasms Lung Cancer (Diagnosis) Lung Diseases Lung Neoplasms Lung Tumors Male Urogenital Diseases Musculoskeletal Cancers Musculoskeletal Diseases Musculoskeletal Tumors Neoplasm Metastasis Neoplasms Neoplasms by Histologic Type Neoplasms by Site Neoplasms, Glandular and Epithelial Neoplastic Processes Pathologic Processes Pathological Conditions, Signs and Symptoms Recurrence Renal Cancer Renal Cell Carcinoma (Kidney Cancer) Renal Cell Carcinoma (RCC) Respiratory Tract Diseases Respiratory Tract Neoplasms Thoracic Neoplasms Urogenital Diseases Urogenital Neoplasms Urologic Diseases Urologic Neoplasms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Hospices Civils de Lyon - Hôpital Édouard Herriot, Lyon, Auvergne-Rhône-Alpes, France

Loading trial locations.

About this study

Interventional oncology (IO) is an established component of cancer care, offering minimally invasive, image-guided treatments for solid tumors in organs such as the liver, kidney, lung, and musculoskeletal system. IO procedures include percutaneous techniques such as thermal ablation, as well as catheter-based approaches such as transarterial embolization, chemoembolization, and radioembolization. Compared to surgical approaches, these procedures are associated with lower morbidity and mortality, shorter hospital admissions, and lower costs.

Medical imaging plays a central role throughout the IO workflow, from diagnosis and treatment planning to procedural guidance and post-treatment assessment. One major advancement in this context is the integration of angiography and CT into a single angio-CT system, allowing seamless transitions between real-time fluoroscopy and high-resolution cross-sectional imaging during procedures.

The newest generation of angio-CT systems incorporates spectral CT technology, which enables energy-resolved imaging through dual-layer detector technology. This simultaneously acquires spectral data while providing conventional CT reconstructions, allowing standard workflow and image interpretation to remain unchanged while spectral information is available as additional imaging data. Spectral CT has the potential to enhance lesion detection and tissue characterization, reduce metal artifacts, and improve the accuracy of treatment evaluation compared with conventional CT.

All procedures are performed according to standard clinical care at the participating centers. Study participation does not influence clinical decision-making, treatment strategy, or follow-up. No experimental interventions are performed.

This is a prospective, observational, multicenter, international registry study coordinated by Leiden University Medical Center (LUMC). Participating centers include Leiden University Medical Center (LUMC, the Netherlands), Hospices Civils de Lyon (HCL, France), and Assistance Publique Hôpitaux de Paris (APHP, France). The study is part of the EU-funded PreciseOnco project, which aims to further integrate and optimize imaging and guidance technologies within clinical IO workflows.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age ≥ 18 years;
  • Undergoing a clinically indicated IO procedure with a percutaneous or transarterial approach for solid tumors;
  • Use of spectral angio-CT image guidance as part of standard care;
  • Written confirmed consent.

Exclusion criteria

  • Patients who are declared incapacitated;
  • Patients suffering from psychic disorders that make a comprehensive judgement impossible.

Treatment and study plan

Primary outcomes

  1. Local tumor control

    Time frame: 6 months, 1 year, 2 years, 3 years

    Local tumor control at the treated site, assessed at 6 months, 1 year, 2 years, and 3 years after the procedure.

Secondary outcomes

  1. Overall survival

    Time frame: 6 months, 1 year, 2 years, 3 years

    Time from the index procedure to death from any cause.

  2. Progression-free survival

    Time frame: 6 months, 1 year, 2 years, 3 years

    Time from the index procedure to disease progression or death from any cause.

  3. Ablation margin and embolization completeness

    Time frame: At time of procedure

    Assessment of ablation margins and completeness of embolization using spectral CT imaging, compared to standard CT reconstructions.

  4. Incidence of periprocedural adverse events

    Time frame: 30 days after procedure

    Periprocedural complications and adverse events graded according to the Common Terminology Criteria for Adverse Events version 6 (CTCAEv6).

  5. Procedure duration

    Time frame: At time of procedure

    Duration of the procedure to evaluate the workflow.

Study contacts

Contact information is provided by the study sponsor or research team.

Emma C.M. Buijsman, MSc

CONTACT

[email protected]

+31 71 526 49 50

Sponsors and collaborators

Lead sponsor

Mark C Burgmans, MD PhD

Other

Collaborators

  • Assistance Publique - Hôpitaux de Paris
  • Cardiovascular and Interventional Radiological Society of Europe
  • EIBIR - European Institute for biomedical imaging research
  • European Commission
  • Hospices Civils de Lyon
  • IGEA
  • Klinikum der Universität zu Köln, Institut für Klinische Chemie
  • Philips Electronics Nederland BV
  • Philips France Commercial
  • Philips GmbH Innovate Technologies
  • Philips Medical Systems
  • Quantum Surgical

Registry information

Official study title

Prospective Registry of Spectral Angio-CT-Guided Interventional Oncology Procedures in Routine Clinical Practice

Acronym: PreciseOnco

Important dates

Study start
2026
Primary completion
2030
Study completion
2030
First posted
Jun 9, 2026
Registry last updated
Jun 9, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.